- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05365178
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
A Randomized, Double-blind, Parallel-controlled Phase III Trial Evaluating the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated HR-positive, HER2-negative Advanced Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Anhui
-
Bengbu, Anhui, China, 233099
- The first affiliated hospital of bengbu medical college
-
Wuhu, Anhui, China, 241000
- The First Affiliated Hospital of Wannan Medical College
-
-
Beijing
-
Beijing, Beijing, China, 100034
- Peking University First Hospital
-
Beijing, Beijing, China, 100142
- Beijing Cancer Hospital
-
-
Chongqing
-
Chongqing, Chongqing, China, 400000
- Chongqing University Cancer Hospital
-
Chongqing, Chongqing, China, 400083
- The Southwest Hospital of AMU
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Fujian Provincial Cancer Hospital
-
-
Gansu
-
Lanzhou, Gansu, China, 730030
- Lanzhou University Second Hospital
-
Lanzhou, Gansu, China, 730000
- Gansu Provincial Cancer Hospital
-
Wuwei, Gansu, China, 730000
- Gansu Wuwei Tumour Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510630
- The Third Affiliated Hospital of Sun Yat-Sen University
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
Guangzhou, Guangdong, China, 510080
- Nanfang Hospital Southern Medical University
-
Jieyang, Guangdong, China, 522095
- Jieyang People's Hospital
-
Maoming, Guangdong, China, 525000
- Maoming People's Hospital
-
Shaoguan, Guangdong, China, 512025
- Yue Bei People's Hospital
-
Shenzhen, Guangdong, China, 518020
- Shenzhen People's Hospital
-
Shenzhen, Guangdong, China, 518036
- PeKing University ShenZhen Hosipital
-
Zhongshan, Guangdong, China, 528403
- Zhongshan City People's Hospital
-
Zhuhai, Guangdong, China, 519099
- The Fifth Affiliated Hospital of Sun Yat-sen University
-
-
Guangxi
-
Guilin, Guangxi, China, 541199
- The Second Affiliated Hospital of Guilin Medical University
-
Yulin, Guangxi, China, 537000
- Yulin First People's Hospital
-
-
Hebei
-
Baoding, Hebei, China, 071000
- The Affiliated Hospital of Hebei University
-
Cangzhou, Hebei, China, 061013
- Cangzhou Central Hospital
-
Cangzhou, Hebei, China, 061013
- Hebei Cangzhou Hospital of Integrated Traditional Chinese
-
Chengde, Hebei, China, 067020
- Affiliated Hospital of Chengde Medical University
-
Langfang, Hebei, China, 065000
- Hebei Petro China Central Hospital
-
Shijiazhuang, Hebei, China, 050011
- The Fourth Hospital of Hebei Medical University
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150086
- The Second Affiliated Hospital of Harbin Medical University
-
Harbin, Heilongjiang, China, 150081
- Affiliated Cancer Hospital of Harbin Medical University
-
Jiamusi, Heilongjiang, China, 154007
- Jiamusi Cancer Hospital
-
-
Henan
-
Luoyang, Henan, China, 471003
- Luoyang Central Hospital
-
Nanyang, Henan, China, 473000
- Nanyang Central Hospital
-
Zhengzhou, Henan, China, 450052
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou, Henan, China, 45008
- Henan Cancer Hospital
-
-
Hubei
-
Yichang, Hubei, China, 443003
- Yichang Central People's Hospital
-
-
Hunan
-
Changde, Hunan, China, 415003
- The First People's Hospital of Changde
-
Changsha, Hunan, China, 410000
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, China, 410000
- Xiangya Hospital of Central South University
-
Changsha, Hunan, China, 410031
- Hunan Cancer Hospital
-
-
Jiangsu
-
Changzhou, Jiangsu, China, 213000
- Changzhou Cancer hospital
-
Huai'an, Jiangsu, China, 223300
- Huai'an First People's Hospital
-
Nanjing, Jiangsu, China, 210008
- Nanjing Drum Tower Hospital
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital
-
Nantong, Jiangsu, China, 226001
- Affiliated hospital of Nantong University
-
Xuzhou, Jiangsu, China, 221004
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jiangxi
-
Ganzhou, Jiangxi, China, 341099
- The First Affiliated Hospital of Gannan Medical University
-
Nanchang, Jiangxi, China, 330000
- The Third Hospital of Nanchang
-
-
Jilin
-
Changchun, Jilin, China, 130021
- the First Hospital of Jilin University
-
Changchun, Jilin, China, 130012
- Jilin Cancer Hospital
-
Changchun, Jilin, China, 130041
- Second Hospital of Jilin University
-
-
Liaoning
-
Dalian, Liaoning, China, 116001
- Affiliated Zhongshan Hospital of Dalian University
-
Dalian, Liaoning, China, 116000
- The Second Hosptial of Dalian Medical University
-
Jinzhou, Liaoning, China, 121012
- The First Affiliated Hospital of Jinzhou Medical University
-
Shenyang, Liaoning, China, 110042
- Liaoning Cancer Hospital & Institute
-
Shenyang, Liaoning, China, 110002
- The First Affiliated Hospital of China Medical University
-
-
Neimenggu
-
Chifeng, Neimenggu, China, 024005
- Affiliated Hospital of Chifeng University
-
Hohhot, Neimenggu, China, 010000
- Inner Mongolia Autonomous Region Cancer Hospital
-
Hohhot, Neimenggu, China, 010000
- The Affilliate Hospital of Inner Mongolia Medical Univercity
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750003
- General Hospital of Ningxia Medical
-
-
Qinghai
-
Xining, Qinghai, China, 810000
- Qinghai University Affiliated Hospital
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Xi'an, Shaanxi, China, 710100
- Xi'An International Medical Center Hospital
-
Xi'an, Shaanxi, China, 710032
- First Affiliated University Hospital of PLA Air Force Military Medical
-
Xi'an, Shaanxi, China, 710038
- Second Affiliated Hospital of PLA Air Force Military Medical
-
-
Shandong
-
Binzhou, Shandong, China, 256699
- Binzhou Medical College Affiliated Hospital
-
Jinan, Shandong, China, 250117
- Shandong Cancer Hospital
-
Jining, Shandong, China, 272000
- Affiliated Hospital of Jining Medical University
-
Linyi, Shandong, China, 276000
- Linyin Cancer Hospital
-
Qingdao, Shandong, China, 266071
- Qingdao University Affiliated Hospital
-
Weifang, Shandong, China, 261000
- Weifang Hospital of Traditional Chinese Midicine
-
Yantai, Shandong, China, 264008
- Yantai Yantai Mountain hospital
-
Zibo, Shandong, China, 255020
- Zibo Central Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- Huadong Hospital
-
Shanghai, Shanghai, China, 200433
- Shanghai Changhai Hospital
-
Shanghai, Shanghai, China, 200123
- Shanghai Oriental Hospital
-
-
Shanxi
-
Changzhi, Shanxi, China, 046000
- Changzhi People's Hospital
-
Taiyuan, Shanxi, China, 030013
- Shanxi Cancer hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 610083
- Chinese People's Liberation Army Western Theater General Hospital
-
Luzhou, Sichuan, China, 646000
- The Affiliated Hospital Of Southwest Medical University
-
Suining, Sichuan, China, 629000
- Suining Central Hospital
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Tianjin Medical University Cancer Hospital
-
Tianjin, Tianjin, China, 300308
- Tianjin Medical University Cancer Hospital Konggang Hospital
-
-
Xinjiang
-
Urumqi, Xinjiang, China, 830011
- Cancer Hospital affiliated to Xinjiang Medical University
-
-
Yunan
-
Kunming, Yunan, China, 650106
- Yunnan Cancel Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Zhejiang Cancer Hospital
-
Hangzhou, Zhejiang, China, 310009
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, China, 310006
- Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medcine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects voluntarily participate in this study and sign informed consent with good compliance;
- Age: 18-75 years (when signing the informed consent); an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Is expected to survive more than 3 months;
- Postmenopausal or premenopausal/perimenopausal women;
- Patients with HR-positive or HER2-negative breast cancer confirmed by pathological examination with evidence of local lesion recurrence or distant metastasis, not suitable for the surgery or radiotherapy for the purpose of cure, and there are no clinical indications of chemotherapy;
- Have a measurable lesion (RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 criteria), or have only bone metastases;
The main organs function well and meet the following standards:
Routine blood examination should meet the following criteria: (No blood transfusion and no hematopoietic stimulation drugs within 7 days before screening)
- Hemoglobin (HB) ≥100 g/L;
- Absolute value of neutrophils (NEUT) ≥ 1.5×109/L;
- Platelet count (PLT) ≥ 90 ×109/L.
Biochemical blood tests shall meet the following criteria:
- Total bilirubin (TBIL) ≤ 1.5 times normal upper limit (ULN);
- Alanine transferase (ALT) and aspartate transferase (AST) ≤ 2.5×ULN; ALT and AST≤ 3×ULN for patients with liver metastasis;
- Serum creatinine (Cr) ≤ 1.5×ULN, or creatinine clearance (Ccr) ≥ 60 mL /min;
Coagulation function tests shall meet the following criteria:
(a) Prothrombin time (PT), activated partial thrombin time (APTT), international standardized
- Color doppler echocardiography: Left ventricular ejection fraction (LVEF) ≥50%;
- Female subjects within reproductive age should agree to use contraceptive methods (such as intrauterine devices, birth control pills or condoms) from participating the study to 6 months after the end of the study; Serum pregnancy test result should be negative within 7 days prior to study enrollment and must be non-lactating subjects.
Exclusion Criteria:
Associated diseases and history:
- The presence or current co-occurrence of other malignant tumors within 5 years, except ured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basal membrane)];
- Multiple factors affecting oral and drug absorption (such as inability to swallow, post-gastrointestinal resection, ulcerative colitis, symptomatic/inflammatory bowel disease, chronic diarrhea and intestinal obstruction);
- Patients with a history of severe pneumonia such as interstitial lung disease;
- Unrelieved toxicity higher than GRADE 1 Common Terminology Criteria for Adverse Events (CTCAE) due to any previous anti-tumor treatment, hair loss is not included;
- Major surgery or significant traumatic injury within 28 days prior to randomization;
- Long-term unhealed wounds, ulcers or fractures;
- Occurrence of arteriovenous/venous thrombosis events within 6 months, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.;
- History of psychotropic drug abuse and can't get rid of it or with mental disorders;
Subject with any severe and/or uncontrolled disease, including:
- Arrhythmias requiring treatment with grade≥2 myocardial ischemia, myocardial infarction, and congestive heart failure (NYHA(New York Heart Association) classification) within 6 months prior to study enrollment (including qtc≥480ms during screening period); And uncontrolled high blood pressure;
- Active or uncontrolled severe infection (≥CTCAE grade 2 infection) or unexplained fever > 38.5℃ within 28 days prior to randomization;
- Decompensated cirrhosis (Child-Pugh liver function score B or C), active hepatitis ;
- Patients with renal failure requiring hemodialysis or peritoneal dialysis;
- A history of immunodeficiency, including HIV ( Human Immunodeficiency Virus) positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or hematopoietic stem cell transplantation;
Tumor-related symptoms and treatment;
- Visceral crisis exists;
- Severe bone injury due to bone metastasis of tumor;
- Received radiotherapy (except palliative radiotherapy for non-target lesions) and other anti-tumor therapies (the washout period was calculated from the end of the last treatment) within 2 weeks prior to randomization;
- Prior medical treatment with fulvestrant, everolimus or CDK4/6 inhibitor;
- The presence of clinically uncontrolled pleural, ascites and pericardial effusion requiring repeated drainage or medical intervention (14 days prior to randomization);
- Known allergy to fulvestrant, Luteal Hormone Releasing Hormone (LHRH) agonists (e.g. Goserelin), TQB3616/ placebo or any supplement;
- History of live attenuated vaccine vaccination within 28 days prior to randomization or planned live attenuated vaccine vaccination during the study period;
- Participated in clinical trials of other antitumor drugs within 4 weeks pior to randomization;
- With other serious physical or mental diseases or abnormal laboratory tests that may increase the risk of study participation or interfere with the study results, or unsuitable for the study for other reasons considered by investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TQB3616 capsule + Fulvestrant injection
TQB3616 capsule: 180mg was given orally with meals or within 2 hours after meals, once a day, every 28 days for a cycle. Fulvestrant injection: 500mg intramuscular injection was administered on day 1, every 28 days for a cycle, for the first cycle, was administered on day 1 and day 15 |
Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
TQB3616 capsule is a CDK (cyclin-dependent kinases) 4/6 kinase inhibitor, which can selectively inhibit THE activity of CDK4/6 kinase, make it form a complex with Cyclin D, reduce the phosphorylation level of retinoblastoma protein (Rb) in cancer cells, and prevent cells from entering S phase from G1 phase
|
Placebo Comparator: Placebo capsule + Fulvestrant injection
Placebo capsules: 0mg was given orally with meals or within 2 hours after meals, once a day, every 28 days for a cycle. Fulvestrant injection: 500mg intramuscular injection was administered on day 1, every 28 days for a cycle, for the first cycle, was administered on day 1 and day 15 |
Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
It is a placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival as assessed by the investigator
Time Frame: Baseline up to progressive disease (PD)/die, about 25.8 months
|
The time from enrollment to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.
|
Baseline up to progressive disease (PD)/die, about 25.8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS) by independent imaging assessment
Time Frame: Baseline up to PD/die, about 25.8 months
|
The time from enrollment to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.
|
Baseline up to PD/die, about 25.8 months
|
Overall survival
Time Frame: Baseline up to die, about 36months
|
Overall survival was defined as the time from randomization to death from any cause.
|
Baseline up to die, about 36months
|
3-Year Overall Survival (OS)
Time Frame: Baseline to 3 years
|
The percentage of participants of survival above 3 years
|
Baseline to 3 years
|
Clinical Benefit Rate(CBR)
Time Frame: Baseline to CR/PR/SD,about 1 year
|
Calculated as the percentage of participants with best overall response of CR, PR, stable disease (SD) and Non-CR/Non-progressive disease (PD).
|
Baseline to CR/PR/SD,about 1 year
|
Incidence of adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).
Time Frame: Baseline to the end of the study, about 3 years
|
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).
|
Baseline to the end of the study, about 3 years
|
Objective Response Rate (ORR)
Time Frame: Baseline to CR/PR,about 1 year
|
Baseline to CR/PR,about 1 year
|
|
Duration of Overall Response (DOR)
Time Frame: CR/PR assessment, up to PD/die, about 20 months
|
The time from the date of participants with a first overall response defined as complete response (CR) or partial response (PR) to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.
|
CR/PR assessment, up to PD/die, about 20 months
|
The European Organization for Research and Treatment of Cancer Quality of Life questionnaire
Time Frame: Baseline to the end of the study, about 3 years
|
Sense of satisfaction, life quality of participants since the enrollment of the study
|
Baseline to the end of the study, about 3 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TQB3616-Ⅲ-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HR-positive, HER2-negative Breast Neoplasms
-
Laura M. Spring, MDMerck Sharp & Dohme LLC; Translational Breast Cancer Research Consortium; Breast...RecruitingTriple Negative Breast Cancer | Hormone Receptor Positive (HR+), HER2-negative Breast Cancer | Biopsy-proven, Positive Lymph Node(s)United States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive, HER2-negative Advanced Breast CancerChina
-
Henan Cancer HospitalRecruitingHR Positive HER2 Negative Advanced Breast CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingHR Positive HER2 Negative Advanced Breast CancerChina
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive,HER2-negative in Advanced Breast CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownHR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerChina
-
Olema Pharmaceuticals, Inc.NovartisRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast CancerUnited States, Australia
-
Biocon Biologics UK LtdNot yet recruitingHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
-
Ana C Garrido-Castro, MDMerck Sharp & Dohme LLC; Gilead SciencesActive, not recruitingMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | HR-Positive Breast CancerUnited States
Clinical Trials on Fulvestrant injection
-
Fudan UniversityActive, not recruiting
-
Institut Paoli-CalmettesMerck KGaA, Darmstadt, Germany; National Cancer Institute, FranceNot yet recruiting
-
Kashiv BioSciences, LLCCompletedMetastatic Breast CancerJordan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive, HER2-negative Advanced Breast CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownHR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerChina
-
GOG FoundationNovartisRecruitingEndometroid Endometrial CancerUnited States
-
Genor Biopharma Co., Ltd.RecruitingLocally Advanced or Metastatic Breast CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMetastatic Breast Cancer | Advanced Malignancies | Recurrent Breast CancerChina
-
University of Wisconsin, MadisonContext Therapeutics Inc.TerminatedMetastatic Cancer | ER-positive Breast Cancer | HER2-negative Breast CancerUnited States
-
Ontario Clinical Oncology Group (OCOG)AstraZenecaCompleted